www.onclive.com Open in urlscan Pro
76.76.21.98  Public Scan

Form analysis
2 forms found in the DOM

<form class="form-inline"><input type="text" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none" type="button" class="btn btn-primary">Search</button></form>

<form class="form-inline"><input type="text" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none" type="button" class="btn btn-primary">Search</button></form>

Text Content

Search
Spotlight
OncClub: Join the Chat on Trending Trials in Cancer2023 nominations are open for
Giants of Cancer Care® Complimentary print subscription for home or office
deliveryIn-person and virtual events just for HCPsSubscribe to our eNewsletter
for breaking news and curated content
OncClub: Join the Chat on Trending Trials in Cancer2023 nominations are open for
Giants of Cancer Care® Complimentary print subscription for home or office
deliveryIn-person and virtual events just for HCPsSubscribe to our eNewsletter
for breaking news and curated content
Specialty
View MoreBreast CancerCAR T-cell TherapyChronic Lymphocytic
LeukemiaGastrointestinal CancerGenitourinary CancersGynecologic
OncologyHematologic OncologyImmuno-OncologyLung CancerMultiple MyelomaUrothelial
Cancer
Breast CancerCAR T-cell TherapyChronic Lymphocytic LeukemiaGastrointestinal
CancerGenitourinary CancersGynecologic OncologyHematologic
OncologyImmuno-OncologyLung CancerMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
Rare Cancer Series
OncClubAll Oncology NewsPipeline ReportRare Cancer Series
Media
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Thoracic Night Live
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer
ExchangePodcastsRapid ReadoutsThe TalkThoracic Night Live
Conferences
Conference Coverage
Conference Listing
Conference CoverageConference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer CarePER EventsScientific InterchangesState of the Science
Summit / IPCWebinars
Partners
Publications
Oncology Live
Oncology Fellows
Supplements And Featured Publications
All Publications
Oncology LiveOncology FellowsSupplements And Featured PublicationsAll
Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Interactive ToolsLearning ModulesPresentationsSponsored
Subscribe
eNewsletter
Print Subscription
eNewsletterPrint Subscription
 * Advertise
 * About OncLive
 * Editorial Board
 * CancerNetwork.com
 * CGTlive.com
 * CureToday.com
 * OncNursingNews.com
 * TargetedOnc.com
 * Contact Us
 * Privacy
 * Terms & Conditions
 * Do Not Sell My Information

 * 

© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert
Insights. All rights reserved.

Search



Spotlight
 * OncClub: Join the Chat on Trending Trials in Cancer
 * 2023 nominations are open for Giants of Cancer Care®
 * Complimentary print subscription for home or office delivery
 * In-person and virtual events just for HCPs
 * Subscribe to our eNewsletter for breaking news and curated content

SpecialtySee All >
 * Breast Cancer
 * CAR T-cell Therapy
 * Chronic Lymphocytic Leukemia
 * Gastrointestinal Cancer
 * Genitourinary Cancers
 * Gynecologic Oncology
 * Hematologic Oncology
 * Immuno-Oncology
 * Lung Cancer
 * Multiple Myeloma
 * Urothelial Cancer


 * Advertise
 * About OncLive
 * Editorial Board
 * CancerNetwork.com
 * CGTlive.com
 * CureToday.com
 * OncNursingNews.com
 * TargetedOnc.com
 * Contact Us
 * Privacy
 * Terms & Conditions
 * Do Not Sell My Information
 * 

 * 

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert
Insights. All rights reserved.


LATEST ONCOLOGY NEWS


XEVINAPANT PLUS CHEMORADIOTHERAPY IMPROVES OS IN LOCALLY ADVANCED HEAD AND NECK
CANCER



October 22nd 2022

Caroline Seymour

Xevinapant plus chemoradiotherapy more than halved the risk of death vs placebo
plus chemoradiotherapy without increasing toxicity in patients with
unresectable, locally advanced head and neck squamous cell carcinoma.


IVONESCIMAB GETS BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR EGFR+ ADVANCED
NSCLC



October 21st 2022

Kristi Rosa

The China National Medical Products Administration has granted a breakthrough
therapy designation to ivonescimab for use in combination with chemotherapy in
patients with EGFR-mutated advanced non–small cell lung cancer in whom prior
treatment with an EGFR TKI has failed.


NAB-SIROLIMUS UNDER INVESTIGATION IN TSC1- AND TSC2-MUTATED GYNECOLOGIC CANCERS



October 21st 2022

Ashling Wahner

Kathleen N. Moore, MD, MS, discusses the incidence of TSC1 and TSC2 mutations in
different gynecologic tumor types, the trial design and eligibility criteria for
the PRECISION 1 study, and the importance of genetic testing to identify these
mutations and treat them early.


ENCORAFENIB/BINIMETINIB DELIVERS PROLONGED SURVIVAL IN BRAF V600–MUTANT MELANOMA



October 21st 2022

Lindsay Fischer

The combination of encorafenib and binimetinib led to sustained improvements in
progression-free survival and overall survival, without new safety signals in
patients with BRAF V600–mutant melanoma, according to 5-year follow-up of the
phase 3 COLUMBUS trial.


IMMUNOTHERAPY AND BRAF-TARGETED THERAPY FILL EXPANDED ROLES ACROSS MELANOMA



October 21st 2022

Ryan Scott

Immunotherapy and targeted therapy combinations containing BRAF and MEK
inhibitors have carved out roles in different settings of melanoma, which has
given clinicians different options for treatment sequencing.


LATEST ONCOLOGY VIDEOS

Dr. Lipson on the Impact of Preoperative Nivolumab Plus Relatlimab in NSCLC
Addressing Healthcare Provider Bias in Multiple Myeloma Management
Dr. Schenk on the Effect of Nivolumab Plus Relatlimab in Basal Cell Carcinoma
Multiple Myeloma Clinical Trial Enrollment in the Black American Population
Outcomes of the JAVELIN Bladder 100 Trial
Dr. Garassino on Updates From the KEYNOTE-189 Trial in NSCLC
Dr. Chen on FLASH Trial Results in CTCL
Dr. Chen Explores Possible Genomic Basis for Racial Disparities in CTCL Outcomes
Dr. Chen on Identifying Malignant T-Cell Signatures in CTCL
Dr. Chen Discusses Management of Early Stage, Advanced CTCL
Dr. Chen Discusses Racial Disparities in CTCL
Dr. Chen Highlights Incidence of CTCL
Dr. Giaconne on the Lack of Funding for Rare Cancers Research
Dr. He Discusses Discovery of Cancer-Inducing Mutation in Thymic Epithelial
Cells
Dr. He Discusses Potential Therapeutic Uses for GTF2I L424+ Thymic Cancers
Review of Updated Efficacy and Safety Data from the EMPOWER-CSCC-1 Trial
Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs
Emily Skotte, MSN on Rash Management in Patients Treated With TKIs
Current Treatment Options for Patients with Advanced Cutaneous Squamous Cell
Carcinoma (cSCC)
Dr. Giaccone on Investigational Agents in Thymic Cancers
Dr. Giaccone on the Challenge of Diagnosing Thymic Cancers
Drs Giaccone and He on Raising Awareness in Thymic Cancers
Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC


ALL ONCOLOGY NEWS


SYLVESTER PANCREATIC CANCER RESEARCHER DR. NAGARAJ NAGATHIHALLI AWARDED FLORIDA
DEPARTMENT OF HEALTH GRANT

October 21st 2022

University of Miami Health System

The Florida Department of Health has awarded Nagaraj Nagathihalli, PhD, an
associate professor at Sylvester Comprehensive Cancer Center at the University
of Miami Miller School of Medicine, a $583,200 grant to study tobacco risk,
tumor progression, and therapeutic options for pancreatic cancer.


MITOMYCIN C REDUCES THE NUMBER OF PROCEDURES FOLLOWING NMIBC RECURRENCE

October 21st 2022

Jason Harris

Chemoresection with mitomycin C, a nonsurgical treatment modality, significantly
reduced the need for transurethral resection of bladder tumors or office biopsy
and tumor fulguration following recurrence in patients with recurrent nonmuscle
invasive bladder cancer.


TARGETING TRANSCRIPTION AS A NEW FRONTIER IN ADVANCED PANCREATIC CANCER

October 21st 2022

Jeremy Kratz, MD

A new focus of research has reconsidered the mechanisms in regulating
transcription as a novel target for advanced pancreatic ductal adenocarcinoma.


ADVANCED HCC: CLINICAL TRIAL DATA BEHIND FIRST-LINE THERAPY OPTIONS

October 21st 2022

Josep M. Llovet, MD, PhD

Expert oncologists take a look at clinical trial data as they pertain to
prevalent first-line systemic therapy options in advanced hepatocellular
carcinoma.


CTDNA HELPS PREDICT RECURRENCE IN REAL-WORLD ANALYSIS OF PATIENTS WITH RESECTED
CRC

October 21st 2022

Ryan Scott

Stacey A. Cohen, MD, discusses the results of real-world analysis of patients
with resected stage I-III colorectal cancer, how circulating tumor DNA status
correlated with recurrence rates, and how these real-world data compared with
previous observational studies.


IMPROVING ACCESS TO CLINICAL TRIALS IN MULTIPLE MYELOMA

October 21st 2022

Joseph Mikhael, MD

Centering discussion clinical trials in multiple myeloma, panelists review how
to improve access to these studies for racial and ethnic minority groups.


DR. LLANOS ON THE ROLE OF SOCIAL AND BIOLOGICAL DETERMINANTS ON CANCER RISK

October 20th 2022

Adana A.M. Llanos, PhD, MPH

Adana A.M. Llanos, PhD, MPH, discusses the role of social and biological
determinants on cancer risk.


DR. VUNJAK-NOVAKOVIC ON THE CLINICAL NEED FOR PERSONALIZING CANCER CARE

October 20th 2022

Gordana Vunjak-Novakovic, PhD, BS, MS

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for
personalizing cancer care.


DR. BACCARELLI ON THE EFFECT OF ENVIRONMENTAL FACTORS ON CANCER DIAGNOSES

October 20th 2022

Andrea Baccarelli, MD, PhD

Andrea Baccarelli, MD, PhD, discusses the effect of environmental factors on
cancer diagnoses.


INHIBITING SYK WITH ENTOSPLETINIB MAY IMPROVE CHEMO RESPONSES IN NPM1-MUTANT AML

October 20th 2022

Ashling Wahner

Eytan M. Stein, MD, discusses the rationale for targeting SYK with entospletinib
and the role of MRD status in AML prognosis and treatment, the crucial reasons
for genetic testing in newly diagnosed AML, and the importance of enrolling
patients to the potentially practice-changing AGILITY trial.


SOLO-1 DATA SUPPORT USE OF OLAPARIB MAINTENANCE TO ACHIEVE LONG-TERM REMISSION
IN BRCA+ ADVANCED OVARIAN CANCER

October 20th 2022

Courtney Flaherty

Paul A. DiSilvestro, MD, discussed the pivotal SOLO-1 trial of maintenance
olaparib in patients with BRCA-mutated ovarian cancer, updated survival data
with the agent in this population, and the next steps for future research.


LEUKEMIA EXPERTS DISCUSS EARLY CAREER GROWTH, MENTORSHIP, AND GENDER BIAS IN
ACADEMIA

October 20th 2022

OncLive Staff

Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early
careers, the rollout of molecular profiling and targeted therapy in the early
2000s, and their growth from protégés to mentors.


IMMUNOTHERAPY-BASED COMBINATIONS REMAIN THE FOCUS OF FRONTLINE TREATMENT IN
METASTATIC RCC

October 20th 2022

Ryan Scott

Rana R. McKay, MD, discusses the evolution of frontline treatment options for
metastatic RCC, and the key clinical trials that have shifted the treatment
paradigms in metastatic castration-resistant prostate cancer, nonmetastatic
castration-resistant prostate cancer, and advanced prostate cancer.


FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE CHIEF MEDICAL OFFICER SHARES
SPOTLIGHT WITH GLOBAL INNOVATORS IN GENOMIC HEALTH

October 20th 2022

Florida Cancer Specialists

Lucio Gordan, MD, chief medical officer of Therapeutics & Analytics for Florida
Cancer Specialists & Research Institute, is a featured speaker at the Illumina
Genomics Forum in San Diego.


INROADS TO TARGETING HER2-MUTANT LUNG CANCER BEGIN TAKING SHAPE

October 20th 2022

Brittany Lovely

Targeted treatment options for patients with HER2-mutant non–small cell lung
cancer have been slow to reach benchmarks for approval given the limited patient
populations harboring this disease characteristic.

See All News


x







×
We Value Your Privacy
Settings
NextRoll, Inc. ("NextRoll") and our advertising partners use cookies and similar
technologies on this site and use personal data (e.g., your IP address). If you
consent, the cookies, device identifiers, or other information can be stored or
accessed on your device for the purposes described below. You can click "Allow
All" or "Decline All" or click Settings above to customize your consent.
NextRoll and our advertising partners process personal data to: ● Store and/or
access information on a device; ● Create a personalized content profile; ●
Select personalised content; ● Personalized ads, ad measurement and audience
insights; ● Product development. For some of the purposes above, our advertising
partners: ● Use precise geolocation data. Some of our partners rely on their
legitimate business interests to process personal data. View our advertising
partners if you wish to provide or deny consent for specific partners, review
the purposes each partner believes they have a legitimate interest for, and
object to such processing.
If you select Decline All, you will still be able to view content on this site
and you will still receive advertising, but the advertising will not be tailored
for you. You may change your setting whenever you see the Manage consent
preferences on this site.
Decline All
Allow All
Manage consent preferences